A randomized trial comparing ceftriaxone (3 g given parenterally per day for 7 days) to ciprofloxacin (500 mg given orally twice a day for 7 days) in the treatment of blood culture positive typhoid fever was conducted. Twenty patients were openly randomized to receive ciprofloxacin and 22 to receive ceftriaxone. The outcome was classified as clinical failure in 6 patients (27 %) in the ceftriaxone group, but in none in the ciprofloxacin group (p = 0.01). The mean duration of fever was four days in the ciprofloxacin group and about five days in the ceftriaxone group (p = 0.04). In the six patients in the ceftriaxone group who experienced failure, therapy was switched to ciprofloxacin and the patients became afebrile and asymptomatic within 48 hours.
Patients with resistant strains of Salmonella typhi and patients with sensitive strains responded equally well to ciprofloxacin therapy. Analysis of a subset of 12 of the multiresistant strains revealed that resistance was encoded for by a transferable 180 kilobase plasmid. Ciprofloxacin represents a useful treatment option in areas where multiresistant strains are likely to be encountered.
Typhoid fever is traditionally treated with a twoWeek course of either chloramphenicol, cotrirnoxazole or ampicillin/amoxiciilin. Despite minor differences in toxicity, duration of fever, carriage and relapse rate, these agents are roughly equal in clinical efficacy (1) . Resistance to these agents has occurred sporadically over the past two deCades in a variety of locations (1, 2) , but beginning in 1989, Salmonella typhi strains resistant to all three standard antimicrobial agents have been reported with alarming frequency from locations as diverse as the Indian subcontinent, the Arabian (Persian) Gulf, the UK and China (1) (2) (3) (4) . These multiresistant strains are fully pathogenic, often Causing illness more severe than that due to sensitive strains (5).
Treatment of typhoid caused by multiresistant
Salmonella typhi strains is not standardized. Both third-generation cephalosporins (particularly ceftriaxone) and the new fluoroquinolones have been used with some success (1, 2), but no study has yet been published which makes a direct comparison of these two classes of antibiotics in the therapy of typhoid fever. In response to the rapid dissemination of multiresistant Salmonella typhi in Bahrain (4), we initiated a trial comparing oral ciprofloxacin with parenteral ceftriaxone for the treatment of typhoid fever. We also investigated the nature of antibiotic resistance in selected multiresistant Salmonella typhi recently introduced into the Arabian Gulf area. 
Results

Patients and Bacterial Strains:
A total of 43 patients met the study entry criteria. One patient was subsequently excluded when he proved to have active tuberculosis in addition to Salmonella typhi bacteremia and failed to become afebrile after more than two weeks of therapy with both ciprofloxacin and ceftriaxone. Of 42 evaluable patients, 20 were randomized to receive ciprofloxacin and 22 to receive ceftriaxone. There were no significant differences when the treatment groups were compared by age, duration of fever prior to admission, prevalence of multiresistant strains, white blood cell count, serum sodium level, hematocrit, or proportion of patients with diarrhea, constipation, splenomegaly or occult blood in the stool ( Outcome of Therapy. There were no cases of clinical failure in the ciprofloxacin group, whereas there were six cases of failure in the ceftriaxone group (p = 0.01). All ciprofloxacin patients were asymptomatic and afebrite by day 6 (mean: 4 days of fever). The ceftriaxone group required a significantly longer time for resolution of fever (mean: about 5 days, p = 0.04). Five of the six cases of failure in the ceftriaxone group were thus classified because of persistent fever after a full seven days of therapy; the sixth patient had fever and persistent severe neuropsychiatric symptoms on day 6 of ceftriaxone therapy and was deemed a case of clinical failure by the investigators (Table   2 ).
All six cases of failure in the ceftriaxone group Were subsequently allocated to receive ciprofloxacin therapy. These six patients were afebrile and asymptomatic within 48 hours, and all patients had an uneventful recovery while completing a one-week course of ciprofloxacin.
Blood cultures were done on day 3 of initial therapy in all 42 study patients and on day 8 in the six patients receiving ciprofloxacin after failure of ceftriaxone; all cultures were negative.
One patient in the ceftriaxone group experienced relapse four weeks after therapy, both blood and Stool cultures being positive for a SalmoneUa typhi strain with the same antibiogram as the initial isolate. One patient in the ciprofloxacin group was readmitted with fever eight weeks after discharge. This patient's stool grew a sensitive Salmonella typhi; however, her prior isolate was triresistant and infection was attributed to reinfection rather than relapse. All other patients had negative stool cultures four weeks after therapy and did not relapse within a two-month follow-up period.
The study was terminated when the clinicians inVolved in the study felt that it was no longer ethical to randomize patients to receive ceftriaxone, given the higher cost, need for intravenous access and lower efficacy of this regimen.
Phage Types and Drug Resistance. Seven of the 12
randomly selected strains belonged to Vi-phage type El, three to type M1, one to type A, and one to type 51. All these strains were resistant to chloramphenicol, ampicillin and trimethoprim, but were sensitive to ceftriaxone, nalidixic acid and ciprofloxacin. The complete spectrum of resistance was transferable at 28 °C but not at 37 °C. In all cases, the spectrum of resistance was en- 
Discussion
In this study, ciprofloxacin given orally produced more rapid and reliable resolution of fever than parenteral ceftriaxone. Prolonged fever in ceftriaxone treated typhoid patients has been observed in other studies (10, 11) and may reflect the relatively poor intracellular penetration of cephalosporins. Ciprofloxacin, with its excellent intracellular penetration, has been almost uniformly successful in the treatment of typhoid caused by both sensitive and resistant Salmonella typhi isolates (1, 12, 13) . The short course (7 days) of ciprofloxacin used in our study was efficacious and not associated with a high rate of stool carriage or relapse, thus having significant advantages compared to the longer two-week course of traditional agents. Because of these advantages, ciprofloxacin has recently been advocated in the UK as the drug of choice for treatment of typhoid in patients with a high pretreatment likelihood of infection with strains resistant to traditional agents (14) . Despite its advantages, ciprofloxacin does have appreciable drawbacks. Its use in children and pregnancy is controversial due to concern about possible cartilage injury. While much less expensive than ceftriaxone, ciprofloxacin is still more expensive than oral drugs of choice used in the past. Although touted as a drug for treatment of typhoid carriers (15) , its failure to reliably eliminate stool carriage in a recent outbreak of
Salmonella java is also disquieting (16). Most dis-
concerting of all is a report from India of decreasing susceptibility of Salmonella typhi to ciprofloxacin and the need for higher doses (1.5 g/day) to achieve a cure (17) . In spite of these potential problems, on the basis of the findings of this study, oral ciprofloxacin (500 mg orally b.i.d.) can be recommended for the initial therapy of typhoid in areas where resistant strains are responsible for a sizeable proportion of cases of typhoid fever. It is an effective oral drug which can cure typhoid in a one-week course of therapy. The rapid spread of multiresistant typhoid fever over large geographic areas presents multiple challenges, especially in less developed countries where access to newer and more expensive antimicrobial agents may be limited. Further research efforts must continue to focus on oral agents with good intracellular penetration which can be used for short courses of therapy with the chances of a high cure rate.
